Sansure Biotech announced that shareholder Chen Wenyi's 5.71 million shares, representing 0.99% of the company's total share capital, are subject to judicial enforcement. The enforcement stems from debt repayment obligations of Chen Wenyi and entities under his control to the creditor applicant. The court will permit the applicant to sell the shares in batches through block trades or centralized bidding on the secondary market, with the reduction period no later than December 30, 2027. In the first quarter of 2026, Sansure Biotech achieved revenue of 437 million yuan and net profit attributable to the parent company of 49.74 million yuan.
Sansure Biotech IncShareholder faces judicial enforcement of 5.71 million shares due to debt obligations, potentially leading to share sales.
